Design Therapeutics, Inc. DSGN
Updated: 9 Aug 2026
No signal published yet
We already track Design Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Design Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Design Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 3, 2026, Design Therapeutics reported its second-quarter 2026 financial results, holding $207.4 million in cash, cash equivalents, and investment securities as of June 30, 2026. The company announced modifications to its RESTORE-FA trial evaluating DT-216P2 for Friedreich's ataxia following positive four-week data reported in May 2026. Additionally, patient dosing was initiated in a Phase 1 trial for DT-818 targeting myotonic dystrophy type 1.
What Firelda Watch includes for Design Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Design Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Design Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more